About Illuminare Biotechnologies
Illuminare Biotechnologies is a private company based in Brooklyn, New York. It has reported $6,023,677 raised in three offerings on Form D since August 2017. Its chief executive is Brian Longstreet.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 7, 2026 | Jun 4, 2026 | $3,650,000of $4.0M target | 42 | $86,905 | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 17, 2018 | Dec 17, 2018 | $0of $2.5M target | 0 | — | DebtRule 506(b), 04.3 | Form D ↗ |
| Aug 14, 2017 | Aug 18, 2017 | $2,373,677of $2.5M target | 44 | $53,947 | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $6,023,677 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Illuminare Biotechnologies's Form D filed Jun 4, 2026.
EA
Oliver Curme
Director
Eric Edidin
Director
AF
Andrew Fradkin
Promoter
Shay Grinfeld
Director and promoter
RG
Robert Graifman
Director and promoter
Earlier filings also listed Sue Yao (director, last listed Aug 2017).